Q1 EPS Estimates for Legend Biotech Lowered by HC Wainwright

Posted by Brian Himes on Aug 21st, 2026

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) – Equities research analysts at HC Wainwright decreased their Q1 2027 earnings estimates for Legend Biotech in a research report issued on Tuesday, August 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of $0.26 per share for the quarter, down from their prior forecast of $0.38. HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Legend Biotech’s Q2 2027 earnings at $0.36 EPS.

Other analysts have also recently issued research reports about the company. Raymond James Financial reaffirmed an “outperform” rating and issued a $58.00 target price on shares of Legend Biotech in a research report on Monday, July 27th. TD Cowen dropped their price target on Legend Biotech from $29.00 to $24.00 and set a “hold” rating on the stock in a research report on Wednesday, August 12th. Barclays reduced their price objective on Legend Biotech from $80.00 to $78.00 and set an “overweight” rating for the company in a research note on Wednesday, August 12th. UBS Group restated a “neutral” rating and set a $28.00 price objective (down from $49.00) on shares of Legend Biotech in a research report on Monday, July 27th. Finally, Oppenheimer cut Legend Biotech from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $75.00 to $40.00 in a research note on Wednesday, August 12th. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $52.29.

Check Out Our Latest Stock Analysis on LEGN

Legend Biotech Stock Down 5.9%

Shares of NASDAQ:LEGN opened at $21.26 on Friday. The company’s fifty day moving average is $24.86 and its two-hundred day moving average is $23.28. Legend Biotech has a 12-month low of $16.24 and a 12-month high of $37.50. The company has a market cap of $3.95 billion, a P/E ratio of -85.04 and a beta of 0.37.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. Legend Biotech had a negative net margin of 7.21% and a negative return on equity of 8.71%. The firm had revenue of $387.50 million during the quarter, compared to analyst estimates of $355.96 million. During the same quarter last year, the business posted $0.03 EPS. The company’s revenue was up 51.9% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Suvretta Capital Management LLC raised its stake in shares of Legend Biotech by 73.1% during the 4th quarter. Suvretta Capital Management LLC now owns 6,608,629 shares of the company’s stock worth $143,672,000 after purchasing an additional 2,790,620 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Legend Biotech by 1.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 6,164,677 shares of the company’s stock valued at $134,020,000 after purchasing an additional 70,191 shares during the period. Goldman Sachs Group Inc. grew its holdings in Legend Biotech by 120.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,174,535 shares of the company’s stock valued at $47,274,000 after buying an additional 1,188,449 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Legend Biotech in the 2nd quarter valued at approximately $55,307,000. Finally, Alliancebernstein L.P. increased its position in Legend Biotech by 4.6% in the 3rd quarter. Alliancebernstein L.P. now owns 1,632,967 shares of the company’s stock worth $53,251,000 after buying an additional 72,371 shares during the period. Hedge funds and other institutional investors own 70.89% of the company’s stock.

Insider Buying and Selling at Legend Biotech

In related news, CEO Ying Huang sold 5,566 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the sale, the chief executive officer directly owned 241,872 shares in the company, valued at approximately $3,574,868.16. This trade represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.02% of the company’s stock.

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.